Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Super Group (SGHC) Limited Ordinary Shares (SGHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Super Group (SGHC) Limited Ordinary Shares — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Super Group (SGHC) Limited Ordinary Shares trades at $11.1 (market cap $5.69B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 5.5× Super Group (SGHC) Limited Ordinary Shares's market cap, and Super Group (SGHC) Limited Ordinary Shares pays the higher dividend (1.79%). Which is the better fit depends on your goals.
| GEHC | SGHC | |
|---|---|---|
Market Cap | $31.07B | $5.69B |
Volume | 3,443,020 | 2,162,759 |
Sector | Health | Consumer Cyclical |
52-Week High | $88.16 | $15.59 |
52-Week Low | $59.48 | $8.52 |
Enterprise Value | $39.53B | $5.23B |
Dividend Yield | 0.23% | 1.79% |
Typical Hold Time | — | 6 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
SGHC trades at $11.19, down 0.27% with a bearish technical signal despite strong fundamentals. The company shows robust profitability with 53.31% gross margins and 48.9% ROE, while revenue grew to $2.23B in 2025. Recent earnings missed expectations but analyst consensus remains unanimously bullish with 8 buy ratings. Technical indicators show selling pressure with moving averages signaling bearish momentum.
SGHC presents a compelling value opportunity with attractive valuation multiples (P/E 15.55, EV/EBITDA 8.43) and strong cash flow generation. However, recent earnings misses and bearish technical signals create near-term headwinds. The stock's outlook depends on Q3 earnings delivery and sustained sports betting momentum amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Super Group (SGHC) Limited Ordinary Shares
Super Group (SGHC) Limited is a holding company for online sports betting and gaming businesses, operating the Betway sports betting brand and the Spin multi-brand online casino portfolio across markets in Europe, the Americas, and Africa.
Read more on SGHC →
